Shanghai Library closed for medical screening
Print Edition
The Shanghai Library was closed for medical screening, the library said in a statement yesterday.
The statement, issued at 12:06am on the library’s official Weibo account, said it will be shut down for the medical screening of relevant people and the venue, as required under the prevention and control measures of the coronavirus in Shanghai and China.
The statement did not mention when it will reopen.
No new locally transmitted cases were reported in Shanghai on Tuesday.
Meanwhile, Shanghaifabu, the official social media account of the Shanghai Information Office, replied to a netizen’s inquiry about the details of an Omicron-infected patient in Guangzhou, who was earlier in Shanghai.
The patient, a 67-year-old man, entered China from Canada on November 27, and had been quarantined at a designated venue in Shanghai.
During the quarantine period, no fever or other symptoms were observed. The patient also took four nucleic acid tests, all of which came back negative.
On December 11, the day he finished quarantine, he traveled from Shanghai to Guangzhou. During his home quarantine on December 13, he tested positive for COVID-19, which later turned out to be the Omicron variant.
Meanwhile, the World Health Organization warned on Tuesday that Omicron was spreading at an unprecedented rate and urged countries to act, as drugmaker Pfizer said its coronavirus pill was effective against the variant.
Omicron, first detected by South Africa and reported to the WHO on November 24, has a large number of mutations, setting alarm bells ringing since its discovery. Early data suggests it can be resistant to vaccines and is more transmissible than the Delta variant.
WHO chief Tedros Adhanom Ghebreyesus told reporters that the strain had been reported in 77 countries and “probably” spread to most nations undetected “at a rate we have not seen with any previous variant.”
Omicron now accounts for around 3 percent of cases in the United States, a figure that is expected to rise rapidly as has been seen in other countries.
Pfizer said clinical trials of its Covid pill reduced hospital admissions and deaths among at-risk people by almost 90 percent. The American drugmaker said its new treatment, Paxlovid, held up against Omicron in lab testing.
Chief executive Albert Bourla called the news a “game changer” and said he expected approval from the US medicines regulator as early as this month.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 沪ICP证：沪ICP备05050403号-1
- |
- 互联网新闻信息服务许可证：31120180004
- |
- 网络视听许可证：0909346
- |
- 广播电视节目制作许可证：沪字第354号
- |
- 增值电信业务经营许可证：沪B2-20120012
Copyright © 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
